Navigation Links
PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
Date:3/20/2008

the advantage of Avecia's core contract manufacturing business. The sale will focus all Avecia's activities on its core areas of contract manufacture of microbial biologics and oligonucleotides," Adrian Buckmaster, CEO of Avecia commented.

Kevin Price, Senior Vice President Vaccines Business, Avecia Biologics Ltd. commented, "We are confident that the combined capabilities of Avecia and PharmAthene will significantly enhance the overall timeliness and opportunity for success of the development and commercialization programs."

Following completion of the sale and purchase agreement, PharmAthene's biodefense portfolio will include:

-- a recombinant Protective Antigen (rPA) anthrax vaccine

-- Valortim(TM), a fully human monoclonal antibody being co-developed with

Medarex for the prevention and treatment of anthrax infection

-- Protexia(R) a novel bioscavenger to prevent and treat organophosphate

nerve agent poisoning

-- a new type of plague vaccine based on recombinant technology

manufactured in E coli

-- A third generation rPA anthrax vaccine program

rPA Anthrax Vaccine

In February 2008 the Department of Health and Human Services (DHHS) issued a formal solicitation (Request for Proposals) for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile (SNS). The solicitation outlines a requirement to procure 25 million doses of an rPA anthrax vaccine.

Avecia's rPA vaccine, which has completed Phase II clinical testing, is a second generation rPA anthrax vaccine for use against human anthrax infection. The objective of the program is to develop, through FDA approval, an rPA-based anthrax vaccine that can be stored, transported and used without the need for a conventional cold chain -- an important advantage for civilian biodefense deployment under the Strategic National Stockpile.

"There is currently a tremendous unmet need for a s
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
2. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
3. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
4. PharmAthene to Present at the BIO CEO & Investor Conference 2008
5. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
6. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
7. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
10. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
11. Corgenix Signs Technology Licensing Agreement With Japanese Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or ... results of its Oral Amphotericin B (Oral Amp ... study, conducted by ImmuneCarta®, the immune monitoring business ... effectiveness of Oral Amp B in reactivating latent ... despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a ... and products for advanced microarray diagnostics, today announced it ... 22 at 2:00 pm ET.  During ... a brief review of SQI,s recent commercialization progress and ... industry veteran recently appointed to the Board of Directors ...
(Date:8/18/2014)... HIV Infection Drug Market and Pipeline Insight is a ... infection and the number of deaths due to AIDS has ... the globe. It has been estimated that the death rate ... with the rates for children being even much lower. A ... has been the improved access to antiretroviral drugs and therapy ...
(Date:8/18/2014)... Aug. 18, 2014 Dyadic International, Inc. ... patented and proprietary technologies are used to develop, ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme ... Registration Statement on Form 10 with the U.S. ... Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO ...
Breaking Biology Technology:iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4
... broad corporate changes are ... ... Board: AVNA) today reported financial results for its first,quarter ended March ... Company refocused its business model from managing the,development of a portfolio ...
... Technology Distributors ... 2007., PLEASANTON, Calif., May 19 Direct Medical ... distribution network covering all,of Russia. This partnership has resulted ... volume sales to a number of medical,providers in Russia., ...
... W. Freston Single Topic Conference Series for ... Gastroenterology ... (AGA) Foundation for Digestive Health and Nutrition (FDHN),announced a gift ... Fund within the AGA Foundation,s overall endowment.,Interest earned from The ...
Cached Biology Technology:Advance Nanotech Reports First Quarter 2008 Financial Results 2Advance Nanotech Reports First Quarter 2008 Financial Results 3Advance Nanotech Reports First Quarter 2008 Financial Results 4Advance Nanotech Reports First Quarter 2008 Financial Results 5Advance Nanotech Reports First Quarter 2008 Financial Results 6Advance Nanotech Reports First Quarter 2008 Financial Results 7Advance Nanotech Reports First Quarter 2008 Financial Results 8Advance Nanotech Reports First Quarter 2008 Financial Results 9Advance Nanotech Reports First Quarter 2008 Financial Results 10Direct Medical Systems Reaches Profitability in 2-1/2 Years, as a Result of Sales of the World's Smallest and Lightest Ultrasound System, the InNovaSound USB Ultrasound. 2Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation 2Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation 3Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation 4
(Date:8/20/2014)... chili pepper causes a burning spiciness that is irresistible ... chili pepper,s effect are using their findings to develop ... which can be caused by inflammation or other problems. ... being tested in clinical trials, in ACS, Journal ... explain that decades ago, scientists had pegged a compound ...
(Date:8/20/2014)... Women who are poor experience higher cortisol levels ... levels of the stress hormone, putting them at ... to a new research from the University of Colorado ... American Journal of Human Biology , is the ... directly to the socioeconomic status of their mothers during ...
(Date:8/20/2014)... North Carolina State University researchers have developed methods for ... monitoring the electrical signals moths use to control those ... of remotely-controlled moths, or "biobots," for use in emergency ... know whether we can control the movement of moths ... operations," says Dr. Alper Bozkurt, an assistant professor of ...
Breaking Biology News(10 mins):CU Denver researcher shows economic disparities impact infant health 2Research paves way for development of cyborg moth 'biobots' 2
... WORCESTER, Mass. Cranberry sauce is not the star ... comes to health benefits, the lowly condiment takes center ... have found that compounds in cranberries are able to ... host of human illnesses (from kidney infections to gastroenteritis ...
... successful wastewater fuel cell, researchers have coaxed common bacteria ... Bruce Logan and colleagues at Penn State University had ... Now, using starter material that could theoretically be sourced ... same microbes to generate hydrogen. By tweaking their ...
... gone" Thats the mystery The Academy of Natural Sciences ... will shed light on the environmental health of the ... less than two inches longonce were abundant in the ... steady decline has prompted Pennsylvania to classify the fish ...
Cached Biology News:Cranberry sauce: good for what ails you 2Cranberry sauce: good for what ails you 3Microbes churn out hydrogen at record rate 2Tiny fish can yield big clues to Delaware River health 2
... Cell Dissociation Buffers are membrane-filtered ... salts chelating agents and cell-conditioning agents ... balanced salt solution or Ca2+- ... dissociation of mammalian cells from support ...
Request Info...
Request Info...
...
Biology Products: